Frontier Pharma Chronic, Acute and Neuropathic Pain Frontier Pharma Chronic, Acute and Neuropathic Pai | Page 2

established product categories, active pharmaceutical ingredients and concomitant mechanisms of
action.
Moderate-to-severe pain has been and continues to be dominated by opioids, which are
increasingly being reformulated to offer abuse-resistance, whereas mild pain is effectively treated
with non-steroidal anti-inflammatory drugs (NSAID). However, significant unmet needs remain, as
chronic pain subtypes - and particularly neuropathic pain - do not respond well to existing
therapies, which do not align to the underlying molecular pathophysiological profile of pain.
However, strong unmet needs remain in core therapy types such as NSAIDs, which are associated
with often severe gastrointestinal adverse events (AE), and opioids, which have a range of AEs
associated with them - in addition to the potential for abuse, which has not been fully alleviated by
the development of abuse-deterrent formulations.
The exceptionally large active pain pipeline, second only to breast cancer in terms of size, consists
of 810 products across all stages of development, indicating that a great deal of resources are
being invested into R&D, with the aim of ultimately overcoming the limitations of existing
therapies.
Related reports by Radiant Insights:
http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare
Moreover, analyses identified 129 first-in-class programs in active development, constituting 20%
of the pipeline for which there is a disclosed molecular target, and acting on 80 distinct first-in-
class molecular targets. Although there is significant differentiation in the scientific rationale and
clinical prospects across these first-in-class products, the majority of first-in-class targets
demonstrate significant preclinical evidence, and alignment to molecular pathophysiological
changes.
Scope
- Analysis of innovation in the pain markets (including both nociceptive and neuropathic pain, of
both a chronic and acute nature), in the context of the overall pipeline and current market
landscape. Also includes analysis of the deals landscape surrounding first-in-class products in pain,
and highlights opportunities for in-licensing.
- A brief introduction to chronic and acute pain, including subtypes, symptoms, pathophysiology,
and an overview of pharmacotherapy and treatment algorithms.
- The changing molecular target landscape between the market and the pipeline, and particular
focal points of innovation in the pipeline.
- Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage
of development, molecule type and molecular target.
Follow Us: